Employees: 6,200
Size EBOS (EBO.AX) is an Australia Health Care company (Medical Specialties) with a market value of $2.50B, the 105th largest of 317 Australia companies the cockpit tracks. Shares closed at A$17.85 on 18 Nov 2026.
Performance Over six months the shares gained 7.1%, against -1.3% for the median peer and +1.2% for the Australia market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 3.1% over the last twelve months (peer median +5.1%); the operating margin is 2.8% (peer median 8.3%).
Valuation It trades at 15.7× forward earnings against a peer median of 24.3× (5th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.6 points below its cost of capital (6.4% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$12.8B | A$12.8B | A$12.5B | A$13.0B | A$12.3B |
| Revenue growth | — | +3% | -4% | +6% | — |
| Gross profit | A$911M | A$909M | A$935M | A$945M | A$921M |
| EBITDA | A$532M | A$530M | A$550M | A$605M | A$574M |
| Net income | A$214M | A$214M | A$218M | A$268M | A$255M |
| Free cash flow | A$214M | A$207M | A$298M | A$249M | A$299M |
| Capital expenditure | A$144M | A$139M | A$148M | A$117M | A$99.0M |
| Total debt | n/a | A$1.89B | A$1.62B | A$1.65B | A$1.28B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EBO.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.8% | -4.1% | 6th highest of 21 |
| 6-month return | +7.1% | -1.3% | 7th highest of 21 |
| Distance from 52-week high | -30.3% | -27.0% | 10th lowest of 21 |
| Revenue growth (TTM) | +3.1% | +5.1% | 9th lowest of 20 |
| Operating margin | 2.8% | 8.3% | 5th lowest of 20 |
| Forward P/E | 15.7× | 24.3× | 5th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 4.7% | 12.2% | 4th least demanding of 15 |
| Growth delivered (Del g) | +6.8% | +10.6% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | -2.2 pp | -0.5 pp | 8th least demanding of 15 |
| ROIC minus cost of capital | -0.6 pp | -0.7 pp | 10th highest of 20 |
| Net debt / EBITDA | 3.1× | 0.4× | 2nd most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |